Our Partners

Hemostasis Fellowship Program


The CHS/AHCDC/CSL Behring Hemostasis Fellowship Program, a fellowship in Congenital and Acquired Bleeding Disorders, was established in the fall of 2001 as a result of a collaborative effort among Novo Nordisk Canada Inc., the Canadian Hemophilia Society and the Association of Hemophilia Clinic Directors of Canada. Since 2010, the Fellowship is made possible because of the generous financial support from CSL Behring Canada. As a global leader in the plasma protein biotherapeutics industry, CSL Behring researches, develops, manufactures and markets biotherapies used to treat serious diseases. Their five core company values underscore their commitment to providing the best possible therapies and services: customer focus; innovation; integrity; collaboration; and superior performance. CSL Behring Canada is proud of its heritage that has delivered biotherapies for life for more than a century. They are committed to providing safe and effective biotherapies to Canadians, now and in the future. The AHCDC and the CHS are proud to be in a partnership with CSL Behring in order to offer this important Fellowship Program.

The goal of this program is to provide fellows in Hematology or other relevant fields the opportunity to obtain additional focused clinical or research training relevant to Hemostasis so that they may improve the care, the treatment and the quality of the lives of patients with hemophilia and other congenital or acquired  bleeding disorders. Consideration will be given on an individual basis to candidates from allied health professions undertaking post-graduate studies.  The fellowship, valued at $75,000, is to be used for salary support for outstanding candidates who plan a career in Canada.

Application forms for the 2015-16 granting period as well as the general criteria and conditions can be accessed by using the links below. Deadline to submit applications: November 14, 2014